VivoSim Lands First China Deals in $2 Billion Toxicology Testing Market
Event summary
- VivoSim secured its first commercial sales in China with two oncology biotech clients, one in Shanghai and another in Chengdu.
- The deals cover GI toxicology screening and efficacy profiling for candidate molecules, representing a significant portion of VivoSim's contracted revenue to date.
- China’s drug regulator approved 76 innovative drugs in 2025, up from 48 in 2024, accelerating demand for non-animal testing methods.
- VivoSim’s NAMkind™ platform combines 3D human organoid models with AI for toxicology and efficacy testing, achieving 91% predictive accuracy in liver model benchmarking.
The big picture
VivoSim’s entry into China marks a strategic milestone in its expansion across Asia-Pacific, tapping into a rapidly growing pharmaceutical market with increasing regulatory support for innovative drug development. The company’s NAMkind™ platform addresses a critical need for human-relevant safety and efficacy data, positioning it to capitalize on the shift away from traditional animal testing methods both domestically and internationally.
What we're watching
- Market Expansion
- Whether VivoSim can scale its presence in China, where the addressable market for liver and gastrointestinal in vitro models is projected to grow at a 10% CAGR.
- Regulatory Tailwinds
- The pace at which Chinese regulators adopt non-animal testing methods, potentially accelerating VivoSim’s growth in the region.
- Global Adoption
- How the FDA’s 2025 plan to phase out animal-testing requirements will impact global demand for VivoSim’s human tissue models.
Related topics